$NSPR

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - Miami, FL — August 17, 2026 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), develope

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001433607 0001433607 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001433607 0001433607 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

InspireMD (Nasdaq: NSPR) said its Compensation Committee approved inducement grants for six new non-executive employees totaling 91,161 shares of restricted stock, dated June 12, 2026, under Nasdaq Rule 5635(c)(4). The awards are under the 2024 Inducement Plan and vest over three years, subject to continued employment.

InspireMD (Nasdaq: NSPR) reported 30-day results from its CGUARDIANS II trial of the CGuard Prime 80 cm implant for TCAR. In 50 high-risk patients, acute device success was 100% (50/50) with no deaths, strokes, MI, or stent thrombosis at 30 days. The company said an FDA PMA supplement is under review, with potential approval in H2 2026.

Stuka Paul purchased 20,000 shares of InspireMD, Inc. (NSPR) at $0.88 on 2026-05-27.

InspireMD director Paul Stuka purchased 75,626 shares of the company's common stock through open-market transactions on May 8 and May 11, 2026. These buys, totaling approximately $88,026, increased his direct beneficial ownership to 632,871 shares. The report also clarified previous ownership figures, noting a correction from an August 2025 filing regarding shares held directly versus indirectly through Osiris Investment Partners, L.P.

InspireMD, Inc. director Gary S. Roubin recently made an open-market purchase of 90,000 shares of common stock at a weighted average price of $1.18 per share. This transaction, executed through multiple trades within a range, increased his direct ownership to 834,478 shares. Such insider buying typically signals confidence in the company's future prospects.

This article provides only the title for information about the number of shareholders of InspireMD Inc. (II2) on GETTEX. The content is primarily navigation and boilerplate text from TradingView, with no specific shareholder data presented in the accessible text.

InspireMD (NSPR) stock has fallen by 15.2% in the past four weeks but is now considered oversold based on its Relative Strength Index (RSI) of 29.32, suggesting a potential rebound. This technical indicator, combined with a 14.6% increase in consensus EPS estimates from sell-side analysts and a Zacks Rank #2 (Buy), indicates that the stock might be poised for a turnaround. Investors may see an opportunity for entry given the exhaustion of selling pressure and positive fundamental shifts.